Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line

The mechanistic/mammalian target of rapamycin (mTOR) is a conserved protein kinase that induces cell growth, proliferation and changes in metabolism in response to mitogenic signals [1]. Unsurprisingly, pathogenesis and progression of numerous cancers, including T-cell acute lymphoblastic leukemia (T-ALL), is associated with constitutive activation of mTOR, caused primarily by mutations in its upstream regulators, such as AKT and PTEN [2,3]. In the majority of T-ALL patients, constitutive mTOR activation negatively affects outcomes [4].
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research